Dr. Richard M. Stone, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (1981)
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 178
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1981Medical school: Harvard Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MA license 53417
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Newton-Wellesley Hospital Newton, MA
Medical groups
- Dana-Farber Cancer Institute, Inc. (684 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 178
- Services billed
- 490
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 325 | 132 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 131 | 35 |
| Established patient office or other outpatient visit, 40-54 minutes | 43 | 32 |
| New patient office or other outpatient visit, 60-74 minutes | 19 | 19 |
| Hospital discharge day management, 30 minutes or less | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Boston, MA | 16 |
| Hydroxyurea Other prescribers in Boston, MA | 15 |
| Imatinib Mesylate | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 13 payments worth $10,947 in total to this clinician.
| Epizyme, Inc. | $3,988 |
|---|---|
| Syndax Pharmaceuticals, Inc. | $3,803 |
| E.r. Squibb & Sons, L.l.c. | $2,865 |
| Celgene Corporation | $292 |
| Consulting Fee | $9,653 |
|---|---|
| Travel and Lodging | $1,041 |
| Food and Beverage | $254 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Jul 1, 2025 | Consulting Fee | $2,865 |
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,800 |
| Epizyme, Inc. Jun 18, 2025 | Consulting Fee Tazverik · Oncology | $2,538 |
| Epizyme, Inc. Jul 2, 2025 | Consulting Fee Tazverik · Oncology | $1,450 |
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to DENVER, CO · in-kind | $377 |
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to DENVER, CO · in-kind | $258 |
| Celgene Corporation Dec 5, 2025 | Travel and Lodging travel to Orlando, FL | $197 |
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to DENVER, CO | $147 |
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to DENVER, CO · in-kind | $61.14 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $230,509 in research payments for these studies, mostly to the institutions running them.
- A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia
Janssen Research & Development, LLC - A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases
Novartis Pharmaceuticals Corporation - A phase 1/2, open-label, dose-escalation and dose-expansion cohort study of SNDX-5613 in patients with relapsed/refractory leukemias, including those harboring an mll/KMT2A gene rearrangement or nucleophosmin 1 (NPM1)…
Syndax Pharmaceuticals, Inc. - A phase i, multicenter, open-label, dose-escalation and expansion, safety, pharmacokinetic, pharmacodynamic, and clinical activity study of orally administered AG-120 in subjects with advanced hematologic malignancies…
Servier Pharmaceuticals LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.